In contrast, if the actions of FRAT1 and BMP2 become stronger and those of FSTL1 and CER1 become weaker in patients with grade III gliomas, the difference in survival and disease progression between these opposing groups may significantly increase. The gene discussed is FSTL1; the disease is central nervous system cancer.